Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Assess the Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients With Recurrent Epithelial Ovarian Cancer

NCT06366490 is registered in ClinicalTrials.gov with PhotonPharma, Inc. as lead sponsor.

NCT NCT06366490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06366490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Assess the Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients With Recurrent Epithelial Ovarian Cancer
Lead sponsor
PhotonPharma, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 12, 2026
Completion date
December 31, 2026
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, recurrent epithelial ovarian cancer which includes epithelial ovarian, fallopian tube and/or primary peritoneal cancer